Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
x-MAP vs Regorafenib in Refractory RAS-Mutant mCRC
NCT06949982Phase 2Recruiting
- Start
- Mar 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxychloroquine in metastatic colorectal cancer (mCRC). Started Mar 2025; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06949982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949982.